Abstract
A phase II trial of recombinant human gamma-interferon in the treatment of unresectable primary hepatocellular carcinoma is reported. The trial was terminated prematurely after recruitment of only 7 patients because of unacceptable toxicity, predominantly renal. There was no evidence of response in any of the 7 patients but some evidence that disease progression was more rapid during the treatment period.
References
1.
Crane
J L
Jr
Glasgow
L A
Kern
ER
Youngner
J S
(1978 ) Journal of the National Cancer Institute
61 , 871 –874
2.
Fleischmann
W R
Jr
Kumpel
G R
Tyring
S K
Baron
S
(1984 ) Transplantation Proceedings
16 , 516 –523
3.
Gatenby
P A
Basten
A
(1984 ) Medical Journal of Australia
140 , 473 –474
4.
Karnofsky
D A
Burchenall
J H
(1949 ) In: Evaluation of Chemotherapeutic Agents . Ed.
Macleod
M C
, Columbia University Press , New York ; pp 199 –205
5.
Miller
A B
Hoogstraten
B
Staquet
M
Winkler
A
(1981 ) Cancer
47 , 207 –214
6.
Okuda
K
(1976 ) In: Hepatocellular Carcinoma . Ed.
Okuda
K
Peters
R L
. Wiley , New York : pp 387 –436
7.
Oldham
R R
(1983 ) Science
219 , 902
8.
Rinderknecht
E
O'Connor
B H
Rodrigues
H
(1984 ) Journal of Biological Chemistry
259 , 6790 –6797
9.
Sikora
K
Smedley
H
(1983 ) British Medical Journal
286 , 739 –740
10.
Son
K
Kew
M
Rabson
A R
(1982 ) Cancer
50 , 2820 –2825
11.
Wilkinson
S P
(1981 ) Journal of Clinical Pathology
34 , 1241 –1244